Static Chart Immatics N.V.

Stocks

Market Closed - Nasdaq 16:00:00 2026-10-26 EDT			5-day change	1st Jan Change
7.150 ^USD	-2.19%		+1.42%	-31.90%

10-24	Immatics N.V. Presents Updated Clinical Trial Data from Ongoing Phase 1B Study with IMA402 PRAME Bispecific and Phase 1 Study with IMA203CD8 PRAME Cell Therapy	CI
10-23	Certain Restricted Share Units of Immatics N.V. are subject to a Lock-Up Agreement Ending on 24-OCT-2026.	CI

Duration

Period